Tirzepatide on TikTok: separating hype from clinical data

What did @kenosi_radebe actually say?

This video is a reply to someone frustrated that tirzepatide hasn't produced weight loss after three months. The creator's argument is essentially: slow results aren't a failure of the drug, they're a signal that your body has underlying metabolic work to do first. She lists several possible culprits, including undiagnosed insulin resistance or PCOS, staying on a low starting dose too long, under-eating (especially protein), using the wrong injection site, and not taking the right supplements. Her core message is that "three months is actually a long time" for some people, but for others with metabolic dysfunction, it simply isn't. That's a reasonable clinical framing. The problem is she bundles genuinely evidence-backed advice with some claims that are shakier than she lets on.

Does the science back this up?

Mostly, yes, with important caveats. The idea that baseline metabolic health shapes GLP-1 response is well-supported. A 2023 analysis by Wadden et al. in Obesity confirmed that people with more severe insulin resistance at baseline showed different weight loss trajectories on tirzepatide compared to those without. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed that at 72 weeks, average weight loss was around 20.9% at the highest dose, but the range was wide. Some participants lost far less, which tells you individual variation is real, not just a talking point. The under-eating concern also has grounding. Severe caloric restriction on GLP-1 medications can accelerate lean mass loss, which is documented in Wilding et al., 2021, NEJM, where body composition changes varied significantly based on diet quality. The injection site claim is the weakest of the bunch scientifically, and the supplement claim is almost entirely unsupported by controlled data.

What did they get wrong (or right)?

She gets the fundamentals right: underlying conditions matter, dose progression matters, and eating enough protein matters. These are not controversial positions in obesity medicine. Where she overreaches is the injection site claim. She says different injection sites "will give you different reactions to the medication," which implies meaningful pharmacokinetic differences. The evidence here is thin. A 2023 review by Morales et al. in Diabetes Technology and Therapeutics found modest absorption rate differences between abdominal, thigh, and arm injection sites for some injectables, but no consistent evidence of clinically meaningful efficacy differences for weekly subcutaneous GLP-1 medications specifically. She presents it as established fact when it is at best speculative. The supplement claim is even less defensible. She says being on "the right supplements" is "crucial" to a GLP-1 journey but gives zero specifics. That is not medical guidance, that is a hook. There is no controlled trial evidence that any supplement stack meaningfully enhances tirzepatide efficacy.

What should you actually know?

If tirzepatide is not producing results after three months, the most evidence-backed questions to ask are: Has the dose been titrated appropriately? Are you in a caloric deficit? Do you have unmanaged insulin resistance or PCOS that needs direct treatment? A provider should be ordering fasting insulin, HbA1c, and a lipid panel if they haven't already. The creator is right that this is a long-term medication. The SURMOUNT-1 trial ran 72 weeks for a reason. Expecting maximum results at week 12 on a starting dose is genuinely unrealistic. However, "give it more time" is not a substitute for a clinical review. If your dose hasn't moved in three months and your provider hasn't checked bloodwork, that is a conversation worth having. Supplements are not a substitute for that conversation, regardless of what any creator recommends.